TABLE 1.
Summary of General information and quality assessment of the included literature.
| References | Country | n | Age (years) | 3D-STI parameter | Chemotherapy protocol | Accompanying diseases | Echo timing | Vendor | Workstation | NOS score |
| Chen et al. (7) | China | 83 | 49.25 ± 8.75 | GLS, GCS, GRS, GAS, LVEF | Epirubicin, cyclophosphamide |
– | Pre- and 6-cycle post-anthracycline | GE Vivid E9 | EchoPAC 110 | 8 |
| Santoro et al. (8) | Italy | 100 | 48.60 ± 11.10 | GLS, GCS, GRS, GAS, LVEF | Fluoruracile, epirubicin, cyclophosphamide |
– | Pre- and 6-cycle post-anthracycline | GE Vivid E9 | EchoPAC 110.1.1 | 6 |
| Piveta et al. (9) | Israel | 47 | 48.70 ± 10.80 | GLS, GCS, GRS, GAS, LVEF | Anthracyclines | – | Pre- and 4-cycle post-anthracycline | GE Vivid E9 | – | 7 |
| Ruan et al. (10) | China | 60 | 53.20 ± 9.60 | GLS, GCS, GRS, GAS, LVEF | Epirubicin, cyclophosphamide |
– | Pre- and 4-cycle post-anthracycline | GE Vivid E9 | EchoPAC 201 | 8 |
| Wang et al. (11) | China | 46 | — | GLS, GCS, GRS, GAS, LVEF | Anthracyclines | – | Pre- and 4-cycle post-anthracycline | GE Vivid E95 | EchoPAC | 6 |
| Chen et al. (12) | China | 63 | 47.60 ± 8.26 | GLS, GCS, GRS, GAS, LVEF | Doxorubicin, cyclophosphamide |
– | Pre- and 4-cycle post-anthracycline | GE Vivid E9 | EchoPAC 110 | 7 |
| Chen et al. (13) | China | 83 | 49.25 ± 8.18 | GLS, GCS, GRS, GAS, LVEF | Epirubicin, cyclophosphamide |
– | Pre- and 6-cycle post-anthracycline | GE Vivid E9 | Echopac 110.1.1 | 7 |
| McGowan et al. (21) | China | 50 | 51.60 ± 9.60 | GLS, GCS, GRS, LVEF | Epirubicin, cyclophosphamide |
– | Pre- and 6-cycle post-anthracycline | GE Vivid E9 | EchoPAC | 8 |
| Stoodley et al. (15) | Australia | 52 | 49.00 ± 9.00 | GLS, GCS, GRS, LVEF | Doxorubicin (77%), epirubicin (23%) | Hypercholesterolemia 21%, hypertension 25%, diabetes 4%, Ischemic heart disease 6% | Pre- and 6-cycle post-anthracycline | GE Vivid 7 | EchoPAC 6.0 | 6 |
| Xue et al. (16) | China | 46 | 50.80 ± 10.40 | GLS, GCS, GRS, LVEF | Anthracyclines | – | Pre- and 6-cycle post-anthracycline | Philips IE33 | Qlab8.0 | 7 |
| Chen et al. (17) | China | 60 | 57.60 ± 8.26 | GLS, GCS, GRS, GAS, LVEF | Epirubicin, cyclophosphamide |
– | Pre- and 4-cycle post-anthracycline | GE Vivid95 | EchoPAC 201 | 6 |
| Zhang et al. (18) | China | 32 | 49.00 ± 6.00 | GLS, GCS, GRS, GAS, LVEF | Fluoruracile, epirubicin, cyclophosphamide |
– | Pre- and 4-cycle post-anthracycline | Toshiba Artida SSH-880 CV | – | 7 |
| Zhang et al. (19) | China | 40 | 44.00 ± 10.00 | GLS, GCS, GRS, GAS, LVEF | Doxorubicin, cyclophosphamide |
– | Pre- and 4-cycle post-anthracycline | GE Vivid E9 | EchoPAC | 6 |
| Sawaya et al. (20) | USA | 43 | 49.00 ± 10.00 | GLS, GCS, GRS, LVEF | Doxorubicin (91%), epirubicin (9%) | Hypertension 28%, hypercholesterolemia 19%, diabetes 2% | Pre- and 4-cycle post-anthracycline | GE Vivid 7/E9 | EchoPAC | 6 |
“-,” Means not mentioned in the literature; Data are presented as mean ± standard deviation; GLS, global longitudinal strain; GCS, global circumferential strain; GRS, global radial strain; GAS, global area strain; LVEF, left ventricular ejection fraction.